Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed EBIT Margin for 3 consecutive years, with 334743.75% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 33508222.0% to 334743.75% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 233.68% through Dec 2025, up 15323.0% year-over-year, with the annual reading at 233.68% for FY2025, 15323.0% up from the prior year.
  • EBIT Margin hit 334743.75% in Q4 2025 for NewAmsterdam Pharma, up from 15845.69% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 334743.75% in Q4 2025 to a low of 15845.69% in Q3 2025.
  • Historically, EBIT Margin has averaged 24893.71% across 3 years, with a median of 1996.0% in 2024.
  • Biggest YoY gain for EBIT Margin was 33508222bps in 2025; the steepest drop was -1575980bps in 2025.
  • Year by year, EBIT Margin stood at 6360.4% in 2023, then soared by 95bps to 338.47% in 2024, then surged by 99000bps to 334743.75% in 2025.
  • Business Quant data shows EBIT Margin for NAMS at 334743.75% in Q4 2025, 15845.69% in Q3 2025, and 186.13% in Q2 2025.